uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Inpremzia
Withdrawn
Human
Biosimilar
Details
EMA number
EMEA/H/C/005331
ATC code
A10AB01
Authorisation
25 April 2022
Revision
-
EMA page
Therapeutic indication
Inpremzia is indicated for the treatment of diabetes mellitus.
MeSH:
Diabetes Mellitus
Group:
Drugs used in diabetes
Special characteristics
Additional monitoring
Active substances
insulin human (rDNA)
Marketing Authorisation Holder
Baxter Holding B.V.
MAH
Timeline
Filter by authority:
EMA
Inpremzia authorised
25 Apr 2022
authorised
regulatory
Inpremzia | uMedical